MAI Capital Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.18M Buy
44,349
+68
+0.2% +$9.52K 0.03% 369
2025
Q4
$5.44M Buy
44,281
+1,967
+5% +$239K 0.03% 377
2025
Q3
$4.7M Buy
42,314
+13,649
+48% +$1.55M 0.03% 382
2025
Q2
$3.18M Buy
28,665
+3,152
+12% +$335K 0.02% 410
2025
Q1
$2.86M Sell
25,513
-789
-3% -$81.4K 0.02% 417
2024
Q4
$2.43M Buy
26,302
+1,862
+8% +$168K 0.02% 444
2024
Q3
$2.05M Sell
24,440
-4,161
-15% -$318K 0.02% 395
2024
Q2
$1.96M Sell
28,601
-4,538
-14% -$303K 0.02% 415
2024
Q1
$2.43M Sell
33,139
-2,060
-6% -$158K 0.03% 366
2023
Q4
$2.85M Sell
35,199
-1,192
-3% -$92.8K 0.04% 266
2023
Q3
$2.73M Buy
36,391
+2,208
+6% +$170K 0.04% 258
2023
Q2
$2.63M Sell
34,183
-6,447
-16% -$514K 0.04% 252
2023
Q1
$3.37M Buy
40,630
+6,961
+21% +$577K 0.05% 227
2022
Q4
$2.89M Buy
33,669
+10,641
+46% +$843K 0.05% 232
2022
Q3
$1.42M Buy
23,028
+8,592
+60% +$542K 0.03% 318
2022
Q2
$892K Buy
14,436
+4,495
+45% +$278K 0.02% 412
2022
Q1
$591K Buy
9,941
+2,402
+32% +$154K 0.01% 513
2021
Q4
$547K Buy
7,539
+1,871
+33% +$129K 0.01% 545
2021
Q3
$396K Buy
5,668
+1,131
+25% +$79.5K 0.01% 565
2021
Q2
$312K Sell
4,537
-2,204
-33% -$147K 0.01% 591
2021
Q1
$436K Sell
6,741
-1,037
-13% -$66.9K 0.01% 495
2020
Q4
$453K Sell
7,778
-3,911
-33% -$236K 0.01% 466
2020
Q3
$739K Sell
11,689
-11,995
-51% -$832K 0.02% 323
2020
Q2
$1.82M Buy
23,684
+3,858
+19% +$296K 0.06% 177
2020
Q1
$1.48M Sell
19,826
-2,864
-13% -$198K 0.06% 178
2019
Q4
$1.47M Sell
22,690
-2,291
-9% -$149K 0.05% 217
2019
Q3
$1.58M Sell
24,981
-1,672
-6% -$109K 0.07% 185
2019
Q2
$1.8M Buy
26,653
+1,072
+4% +$70.5K 0.08% 177
2019
Q1
$1.66M Sell
25,581
-595
-2% -$39.5K 0.09% 170
2018
Q4
$1.64M Sell
26,176
-3,660
-12% -$256K 0.1% 166
2018
Q3
$2.3M Sell
29,836
-1,410
-5% -$106K 0.12% 149
2018
Q2
$2.21M Sell
31,246
-375
-1% -$26.5K 0.12% 152
2018
Q1
$2.38M Buy
31,621
+573
+2% +$45.5K 0.14% 144
2017
Q4
$2.22M Buy
31,048
+7,328
+31% +$556K 0.13% 145
2017
Q3
$1.92M Buy
23,720
+504
+2% +$38.5K 0.12% 145
2017
Q2
$1.64M Buy
23,216
+463
+2% +$30.8K 0.11% 152
2017
Q1
$1.54M Buy
22,753
+2,755
+14% +$194K 0.1% 158
2016
Q4
$1.43M Sell
19,998
-2,740
-12% -$204K 0.1% 153
2016
Q3
$1.8M Sell
22,738
-875
-4% -$71.1K 0.14% 134
2016
Q2
$1.97M Sell
23,613
-4,072
-15% -$361K 0.15% 127
2016
Q1
$2.54M Buy
27,685
+1,014
+4% +$91.4K 0.19% 112
2015
Q4
$2.7M Buy
26,671
+979
+4% +$102K 0.21% 112
2015
Q3
$2.52M Sell
25,692
-7,357
-22% -$817K 0.19% 120
2015
Q2
$3.87M Sell
33,049
-859
-3% -$93.9K 0.25% 106
2015
Q1
$3.33M Buy
33,908
+26,666
+368% +$2.71M 0.22% 112
2014
Q4
$683K Sell
7,242
-1,244
-15% -$129K 0.05% 257
2014
Q3
$903K Sell
8,486
-895
-10% -$87.6K 0.09% 164
2014
Q2
$778K Buy
9,381
+418
+5% +$32.5K 0.07% 173
2014
Q1
$635K Buy
8,963
+2,591
+41% +$203K 0.06% 192
2013
Q4
$479K Buy
+6,372
New +$444K 0.05% 230

Other funds holding GILD

MAI Capital Management's GILD Position: Q1 2026 in Review

MAI Capital Management increased its Gilead Sciences (GILD) stake by 0.15% in Q1 2026, buying an estimated $9.52K and bringing the position to 44,349 shares worth $6.18M. The position accounts for 0.03% of the portfolio, ranked #369.

MAI Capital Management first reported a position in GILD in Q4 2013 and has held it in 50 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • MAI Capital Management held 44,349 shares of Gilead Sciences worth $6.18M as of Q1 2026.
  • MAI Capital Management bought 68 Gilead Sciences shares in Q1 2026, an estimated $9.52K.
  • Gilead Sciences made up 0.03% of MAI Capital Management's portfolio in Q1 2026, its #369 holding.
  • MAI Capital Management first reported a position in Gilead Sciences in Q4 2013 and has held it in 50 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.